Philip James Wealth Mangement’s Vertex Pharmaceuticals VRTX Stock Holding History

Philip James Wealth Mangement’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$727K	Sell	1,464 -1,106	-43%	-$490K	0.08%	94
2026 Q1	$1.15M	Sell	2,570 -58	-2%	-$27K	0.13%	77
2025 Q4	$1.19M	Sell	2,628 -1,431	-35%	-$617K	0.14%	79
2025 Q3	$1.59M	Sell	4,059 -399	-9%	-$167K	0.19%	75
2025 Q2	$1.98M	Buy	4,458 +1,467	+49%	+$676K	0.25%	66
2025 Q1	$1.45M	Buy	+2,991	New	+$1.39M	0.18%	71

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Philip James Wealth Mangement's VRTX Position: Q2 2026 in Review

Philip James Wealth Mangement reduced its Vertex Pharmaceuticals (VRTX) stake by 43% in Q2 2026, selling an estimated $490K and leaving 1,464 shares worth $727K. The position accounts for 0.08% of the portfolio, ranked #94.

Philip James Wealth Mangement first reported a position in VRTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.98M in Q2 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Philip James Wealth Mangement held 1,464 shares of Vertex Pharmaceuticals worth $727K as of Q2 2026.
Philip James Wealth Mangement sold 1,106 Vertex Pharmaceuticals shares in Q2 2026, an estimated $490K.
Vertex Pharmaceuticals made up 0.08% of Philip James Wealth Mangement's portfolio in Q2 2026, its #94 holding.
Philip James Wealth Mangement first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Philip James Wealth Mangement's Vertex Pharmaceuticals position peaked at $1.98M in Q2 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Philip James Wealth Mangement's 13F filing for Q2 2026, filed 27 Jul 2026.